RecruitingNot applicableNCT06162338
A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients with Gaucher Disease Type I
Studying Gaucher disease type 3
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- He Huang
- Principal Investigator
- He Huang, PhD
- Intervention
- LY-M001 Injection(biological)
- Enrollment
- 3 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2023 – 2026
Study locations (1)
- The First Affiliated Hospital of Zhejiang University School of Medicine, Hanzhou, Zhejiang, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06162338 on ClinicalTrials.govOther trials for Gaucher disease type 3
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT07285369High-Dose Ambroxol in Pediatric Type III Gaucher Disease (GD3)Agyany Pharma LTD
- ENROLLING BY INVITATIONNANCT06627543Effect of Enzyme Replacement Therapy on Cardiac Function in Children With Gaucher Disease Type 3Noha Osman
- RECRUITINGNANCT05586243MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)University of Minnesota
- ACTIVE NOT RECRUITINGPHASE3NCT05222906Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3Sanofi
- RECRUITINGNANCT03240653Gaucherite - A Study to Stratify Gaucher DiseaseCambridge University Hospitals NHS Foundation Trust